Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
WuXi XDC Cayman, Inc. ( (HK:2268) ) just unveiled an update.
WuXi XDC Cayman, Inc. has announced a revision and renewal of its Payload-Linkers Master Services Agreement due to the strong growth in its ADC CRDMO business. The company anticipates exceeding its original annual cap for 2025 and plans to extend the agreement with WuXi AppTec for three more years, subject to regulatory requirements. This move reflects the company’s robust performance and strategic positioning in the market, aiming to capitalize on the increasing demand for its services.
The most recent analyst rating on (HK:2268) stock is a Buy with a HK$74.00 price target. To see the full list of analyst forecasts on WuXi XDC Cayman, Inc. stock, see the HK:2268 Stock Forecast page.
More about WuXi XDC Cayman, Inc.
WuXi XDC Cayman, Inc. operates in the biopharmaceutical industry, focusing on ADC CRDMO services. The company is known for its involvement in research and development, particularly in bioconjugate modalities, and has shown significant growth in revenue and net profit.
Average Trading Volume: 6,566,806
Technical Sentiment Signal: Buy
Current Market Cap: HK$68.18B
Find detailed analytics on 2268 stock on TipRanks’ Stock Analysis page.